Litigation Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)
✉ Email this page to a colleague
Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-12-11 |
| Court | District Court, D. Delaware | Date Terminated | 2020-07-06 |
| Cause | 28:2201 Declaratory Judgment | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | MYLAN LABORATORIES LIMITED | ||
| Patents | 8,609,707; 8,791,270; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399 | ||
| Attorneys | John W. Shaw | ||
| Firms | Devlin Law Firm | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-12-11 | 1 | expiration of U.S. Patent Nos. 8,791,270 (“the ’270 patent”); 8,609,707 (“the ’707 patent”); 9,265,831 (“…COUNT II – INFRINGEMENT OF U.S. PATENT NO. 8,609,707 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 8,609,707 204. Plaintiffs incorporate…’270 patent, the ’707 patent, the ’831 patent, the ’796 patent, the ’797 patent, the ’908 patent, the…’568 patent, the ’887 patent, the ’397 patent, the ’398 patent, the ’399 patent, the ’021 patent, and | External link to document | |
| 2017-12-11 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 8,791,270 … 2017 6 July 2020 1:17-cv-01790 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
